Treatment for glioblastoma (GBM)
Intended for US audiences only.

The NovoTAL System

Optimize treatment with Optune using the FDA‐approved NovoTAL System

  • In electric field simulation studies, it was possible to achieve a substantial increase in Tumor Treating Fields (TTFields) intensity to a specific region of the brain by adapting the configuration of paired arrays1

Individualize Optune for every patient

  • Treatment planning is an essential component of therapy with Optune

  • The NovoTAL System is utilized to create individualized treatment maps for all clinical and commercial patients starting Optune

To learn more about the NovoTAL System, please email novotal@novocure.com.

NovoTAL system transducer array layout
NovoTAL system view form

Reference: 1. Wenger C, Salvador R, Basser PJ, Miranda PC. Improving Tumor Treating Fields treatment efficacy in patients with glioblastoma using personalized array layouts. Int J Radiat Oncol Biol Phys, 2016;94(5):1137e1143.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).